Login Register Cart 0
Generic placeholder image

Recent Advances in Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-4344
ISSN (Online): 2772-4352

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Fecal Microbiota Transplant: Latest Addition to Arsenal against Recurrent Clostridium difficile Infection

Author(s): Monica Gulati*, Sachin K. Singh, Leander Corrie, Lipika Chandwani, Apoorva Singh, Bhupinder Kapoor, Rajesh Kumar, Narendra K. Pandey, Bimlesh Kumar, Ankit Awasthi and Rubiya Khursheed

Volume 16, Issue 1, 2021

Published on: 25 September, 2020

Page: [2 - 12] Pages: 11

DOI: 10.2174/1574891X15666200925092354

Price: $65

Abstract

An infectious disease of the colon, recurrent Clostridium difficile infection (RCDI), is hitherto considered insurmountable leading to significant morbidity and mortality. Gut dysbiosis, generally resulting from frequent use of antibiotics, is considered to be responsible for the etiopathogenesis of RCDI. Ironically, the conventional treatment strategies for the disease also include the use of anti- infective drugs such as metronidazole, vancomycin and fidaxomycin. As a result of the efforts to overcome the limitations of these treatment options to control the recurrence of disease, faecal microbiota transplant (FMT) has emerged as an effective and safe alternative. It is pertinent to add here that FMT is defined as the process of engraftment of fecal suspension from the healthy person into the gastrointestinal tract of the diseased individual aiming at the restoration of gut microbiota. FMT has proved to be quite successful in the treatment of recurrent and resistant Clostridium difficile infections. In the last three decades, a lot of information has been generated on the use of FMT for RCDI. A number of clinical trials have been reported with generally very high success rates. However, a very small number of patents could be found in the area, indicating that there still exists lacuna in the knowledge about FMT with respect to its preparation, regulation, mode of delivery and safety. The current review attempts to dive deeper to discuss the patents available in the area while supporting the information contained therein with the non-patent literature.

Keywords: Fecal microbiota transplantation, recurrent Clostridium difficile infection, antibiotics, metronidazole, microbiota, dysbiosis.

« Previous Next »
Graphical Abstract

[1]
Rowland, I.; Gibson, G.; Heinken, A.; Scott, K.; Swann, J.; Thiele, I.; Tuohy, K. Gut microbiota functions: metabolism of nutrients and other food components. Eur. J. Nutr., 2018, 57(1), 1-24.
[http://dx.doi.org/10.1007/s00394-017-1445-8] [PMID: 28393285]
[2]
Redondo-Useros, N.; Nova, E.; González-Zancada, N.; Díaz, L.E.; Gómez-Martínez, S.; Marcos, A. Microbiota and lifestyle: a special focus on diet. Nutrients, 2020, 12(6), 1776.
[http://dx.doi.org/10.3390/nu12061776] [PMID: 32549225]
[3]
Ogunrinola, G.A.; Oyewale, J.O.; Oshamika, O.O.; Olasehinde, G.I. The human microbiome and its impacts on health. Int. J. Microbiol., 2020, 20208045646
[http://dx.doi.org/10.1155/2020/8045646] [PMID: 32612660]
[4]
Kachrimanidou, M.; Tsintarakis, E. Insights into the role of human gut microbiota in Clostridioides difficile infection. Microorganisms, 2020, 8(2), 200.
[http://dx.doi.org/10.3390/microorganisms8020200] [PMID: 32023967]
[5]
Miller, B.A.; Chen, L.F.; Sexton, D.J.; Anderson, D.J. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect. Control Hosp. Epidemiol., 2011, 32(4), 387-390.
[http://dx.doi.org/10.1086/659156] [PMID: 21460491]
[6]
Bignardi, G.E. Risk factors for Clostridium difficile infection. J. Hosp. Infect., 1998, 40(1), 1-15.
[http://dx.doi.org/10.1016/S0195-6701(98)90019-6] [PMID: 9777516]
[7]
Tabak, Y.P.; Srinivasan, A.; Yu, K.C.; Kurtz, S.G.; Gupta, V.; Gelone, S.; Scoble, P.J.; McDonald, L.C. Hospital-level high-risk antibiotic use in relation to hospital-associated Clostridioides difficile infections: Retrospective analysis of 2016-2017 data from US hospitals. Infect. Control Hosp. Epidemiol., 2019, 40(11), 1229-1235.
[http://dx.doi.org/10.1017/ice.2019.236] [PMID: 31522695]
[8]
Marra, A.R.; Perencevich, E.N.; Nelson, R.E.; Samore, M.; Khader, K.; Chiang, H.Y.; Chorazy, M.L.; Herwaldt, L.A.; Diekema, D.J.; Kuxhausen, M.F.; Blevins, A.; Ward, M.A.; McDanel, J.S.; Nair, R.; Balkenende, E.; Schweizer, M.L. Incidence and outcomes associated with Clostridium difficile infections: a systematic review and meta-analysis. JAMA Netw. Open, 2020, 3(1)e1917597
[http://dx.doi.org/10.1001/jamanetworkopen.2019.17597] [PMID: 31913488]
[9]
Younas, M.; Royer, J.; Weissman, S.B.; Waites, K.S.; Dash, S.; Rac, H.; Bookstaver, P.B.; Justo, J.A.; Bell, L.; Maki, A., Jr; Al-Hasan, M.N. Burden of community-associated Clostridioides difficile infection in southeastern United States: a population-based study. Infection, 2020, 48(1), 129-132.
[http://dx.doi.org/10.1007/s15010-019-01368-5] [PMID: 31677084]
[10]
Chahine, E.B. The rise and fall of metronidazole for Clostridium difficile infection. Ann. Pharmacother., 2018, 52(6), 600-602.
[http://dx.doi.org/10.1177/1060028018757446] [PMID: 29424238]
[11]
Czepiel, J.; Dróżdż, M.; Pituch, H.; Kuijper, E.J.; Perucki, W.; Mielimonka, A.; Goldman, S.; Wultańska, D.; Garlicki, A.; Biesiada, G. Clostridium difficile infection: review. Eur. J. Clin. Microbiol. Infect. Dis., 2019, 38(7), 1211-1221.
[http://dx.doi.org/10.1007/s10096-019-03539-6] [PMID: 30945014]
[12]
Sun, X.; Hirota, S.A. The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Mol. Immunol., 2015, 63(2), 193-202.
[http://dx.doi.org/10.1016/j.molimm.2014.09.005] [PMID: 25242213]
[13]
Kelly, C.P.; LaMont, J.T. Clostridium difficile--more difficult than ever. N. Engl. J. Med., 2008, 359(18), 1932-1940.
[http://dx.doi.org/10.1056/NEJMra0707500] [PMID: 18971494]
[14]
Kelly, C.P. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin. Microbiol. Infect., 2012, 18(6)(Suppl. 6), 21-27.
[http://dx.doi.org/10.1111/1469-0691.12046] [PMID: 23121551]
[15]
Vardakas, K.Z.; Polyzos, K.A.; Patouni, K.; Rafailidis, P.I.; Samonis, G.; Falagas, M.E. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int. J. Antimicrob. Agents, 2012, 40(1), 1-8.
[http://dx.doi.org/10.1016/j.ijantimicag.2012.01.004] [PMID: 22398198]
[16]
Mikamo, H.; Tateda, K.; Yanagihara, K.; Kusachi, S.; Takesue, Y.; Miki, T.; Oizumi, Y.; Gamo, K.; Hashimoto, A.; Toyoshima, J.; Kato, K. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan. J. Infect. Chemother., 2018, 24(9), 744-752.
[http://dx.doi.org/10.1016/j.jiac.2018.05.010] [PMID: 29934056]
[17]
Khanna, S.; Pardi, D.S. Clostridium difficile infection: new insights into management. Mayo Clin. Proc., 2012, 87(11), 1106-1117.
[http://dx.doi.org/10.1016/j.mayocp.2012.07.016] [PMID: 23127735]
[18]
Agrawal, M.; Aroniadis, O.C.; Brandt, L.J.; Kelly, C.; Freeman, S.; Surawicz, C.; Broussard, E.; Stollman, N.; Giovanelli, A.; Smith, B.; Yen, E.; Trivedi, A.; Hubble, L.; Kao, D.; Borody, T.; Finlayson, S.; Ray, A.; Smith, R. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J. Clin. Gastroenterol., 2016, 50(5), 403-407.
[PMID: 26352106]
[19]
Eiseman, B.; Silen, W.; Bascom, G.S.; Kauvar, A.J. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery, 1958, 44(5), 854-859.
[PMID: 13592638]
[20]
Schwan, A.; Sjölin, S.; Trottestam, U.; Aronsson, B. Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet, 1983, 2(8354), 845.
[http://dx.doi.org/10.1016/S0140-6736(83)90753-5] [PMID: 6137662]
[21]
Krajicek, E.; Fischer, M.; Allegretti, J.R.; Kelly, C.R. R. Nuts and bolts of fecal microbiota transplantation. Clin. Gastroenterol. Hepatol., 2019, 17(2), 345-352.
[http://dx.doi.org/10.1016/j.cgh.2018.09.029] [PMID: 30268564]
[22]
Mcilroy, J.R.; Segal, J.P.; Mullish, B.H.; Quraishi, M.N.; Gasbarrini, A.; Cammarota, G.; Ianiro, G. Current and future targets for faecal microbiota transplantation. Human Microbiome Journal, 2019, 11100045
[http://dx.doi.org/10.1016/j.humic.2018.08.004]
[23]
McDonald, L.C.; Gerding, D.N.; Johnson, S.; Bakken, J.S.; Carroll, K.C.; Coffin, S.E.; Dubberke, E.R.; Garey, K.W.; Gould, C.V.; Kelly, C.; Loo, V.; Shaklee Sammons, J.; Sandora, T.J.; Wilcox, M.H. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis., 2018, 66(7), e1-e48.
[http://dx.doi.org/10.1093/cid/cix1085] [PMID: 29462280]
[24]
Olesen, S.W.; Panchal, P.; Chen, J.; Budree, S.; Osman, M. Global disparities in faecal microbiota transplantation research. Lancet Gastroenterol. Hepatol., 2020, 5(3), 241.
[http://dx.doi.org/10.1016/S2468-1253(19)30452-2] [PMID: 32061326]
[25]
Cammarota, G.; Ianiro, G.; Tilg, H.; Rajilić-Stojanović, M.; Kump, P.; Satokari, R.; Sokol, H.; Arkkila, P.; Pintus, C.; Hart, A.; Segal, J.; Aloi, M.; Masucci, L.; Molinaro, A.; Scaldaferri, F.; Gasbarrini, G.; Lopez-Sanroman, A.; Link, A.; de Groot, P.; de Vos, W.M.; Högenauer, C.; Malfertheiner, P.; Mattila, E.; Milosavljević, T.; Nieuwdorp, M.; Sanguinetti, M.; Simren, M.; Gasbarrini, A. European consensus conference on faecal microbiota transplantation in clinical practice. Gut, 2017, 66(4), 569-580.
[http://dx.doi.org/10.1136/gutjnl-2016-313017] [PMID: 28087657]
[26]
Silverman, M.S.; Davis, I.; Pillai, D.R. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin. Gastroenterol. Hepatol., 2010, 8(5), 471-473.
[http://dx.doi.org/10.1016/j.cgh.2010.01.007] [PMID: 20117243]
[27]
Kao, D.; Roach, B.; Silva, M.; Beck, P.; Rioux, K.; Kaplan, G.G.; Chang, H.J.; Coward, S.; Goodman, K.J.; Xu, H.; Madsen, K.; Mason, A.; Wong, G.K.; Jovel, J.; Patterson, J.; Louie, T. Effect of oral capsule-vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA, 2017, 318(20), 1985-1993.
[http://dx.doi.org/10.1001/jama.2017.17077] [PMID: 29183074]
[28]
Youngster, I.; Russell, G.H.; Pindar, C.; Ziv-Baran, T.; Sauk, J.; Hohmann, E.L. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA, 2014, 312(17), 1772-1778.
[http://dx.doi.org/10.1001/jama.2014.13875] [PMID: 25322359]
[29]
Allegretti, J.R.; Fischer, M.; Sagi, S.V.; Bohm, M.E.; Fadda, H.M.; Ranmal, S.R.; Budree, S.; Basit, A.W.; Glettig, D.L.; de la Serna, E.L.; Gentile, A.; Gerardin, Y.; Timberlake, S.; Sadovsky, R.; Smith, M.; Kassam, Z. Fecal microbiota transplantation capsules with targeted colonic versus gastric delivery in recurrent Clostridium difficile infection: a comparative cohort analysis of high and lose dose. Dig. Dis. Sci., 2019, 64(6), 1672-1678.
[http://dx.doi.org/10.1007/s10620-018-5396-6] [PMID: 30519847]
[30]
Stollman, N.; Smith, M.; Giovanelli, A.; Mendolia, G.; Burns, L.; Didyk, E.; Burgess, J.; Noh, A.; Edelstein, C.; Alm, E.; Kassam, Z. Frozen encapsulated stool in recurrent Clostridium difficile: exploring the role of pills in the treatment hierarchy of fecal microbiota transplant nonresponders. Am. J. Gastroenterol., 2015, 110(4), 600-601.
[http://dx.doi.org/10.1038/ajg.2015.81] [PMID: 25853204]
[31]
Chehri, M.; Christensen, A.H.; Halkjær, S.I.; Günther, S.; Petersen, A.M.; Helms, M. Case series of successful treatment with fecal microbiota transplant (FMT) oral capsules mixed from multiple donors even in patients previously treated with FMT enemas for recurrent Clostridium difficile infection. Medicine (Baltimore), 2018, 97(31)e11706
[http://dx.doi.org/10.1097/MD.0000000000011706] [PMID: 30075573]
[32]
Khanna, S.; Pardi, D.S.; Kelly, C.R.; Kraft, C.S.; Dhere, T.; Henn, M.R.; Lombardo, M.J.; Vulic, M.; Ohsumi, T.; Winkler, J.; Pindar, C.; McGovern, B.H.; Pomerantz, R.J.; Aunins, J.G.; Cook, D.N.; Hohmann, E.L. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J. Infect. Dis., 2016, 214(2), 173-181.
[http://dx.doi.org/10.1093/infdis/jiv766] [PMID: 26908752]
[33]
Hirsch, B.E.; Saraiya, N.; Poeth, K.; Schwartz, R.M.; Epstein, M.E.; Honig, G. Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect. Dis., 2015, 15(1), 191.
[http://dx.doi.org/10.1186/s12879-015-0930-z] [PMID: 25885020]
[34]
Staley, C.; Hamilton, M.J.; Vaughn, B.P.; Graiziger, C.T.; Newman, K.M.; Kabage, A.J.; Sadowsky, M.J.; Khoruts, A. Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study. Am. J. Gastroenterol., 2017, 112(6), 940-947.
[http://dx.doi.org/10.1038/ajg.2017.6] [PMID: 28195180]
[35]
Staley, C.; Vaughn, B.P.; Graiziger, C.T.; Singroy, S.; Hamilton, M.J.; Yao, D.; Chen, C.; Khoruts, A.; Sadowsky, M.J. Community dynamics drive punctuated engraftment of the fecal microbiome following transplantation using freeze-dried, encapsulated fecal microbiota. Gut Microbes, 2017, 8(3), 276-288.
[http://dx.doi.org/10.1080/19490976.2017.1299310] [PMID: 28282270]
[36]
Jiang, Z.D.; Jenq, R.R.; Ajami, N.J.; Petrosino, J.F.; Alexander, A.A.; Ke, S.; Iqbal, T.; DuPont, A.W.; Muldrew, K.; Shi, Y.; Peterson, C.; Do, K.A.; DuPont, H.L. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial. PLoS One, 2018, 13(11)e0205064
[http://dx.doi.org/10.1371/journal.pone.0205064] [PMID: 30388112]
[37]
Ramai, D.; Zakhia, K.; Fields, P.J.; Ofosu, A.; Patel, G.; Shahnazarian, V.; Lai, J.K.; Dhaliwal, A.; Reddy, M.; Chang, S. Fecal microbiota transplantation (FMT) with colonoscopy is superior to enema and nasogastric tube while comparable to capsule for the treatment of recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Dig. Dis. Sci., 2020.
[http://dx.doi.org/10.1007/s10620-020-06185-7] [PMID: 32166622]
[38]
Select, D. FMT: colonoscopy or capsule? JAMA, 2017, 318, 1985-1993.
[39]
Burns, L.J.; Dubois, N.; Smith, M.B.; Mendolia, G.M.; Burgess, J.; Edelstein, C.; Noh, A. Alm, E.; Kassam, Z. 499 donor recruitment and eligibility for fecal microbiota transplantation: results from an international public stool bank. Gastroenterology, 2015, 148(4), S-96-S-97.
[http://dx.doi.org/10.1016/S0016-5085(15)30331-0]
[40]
DeFilipp, Z.; Bloom, P.P.; Torres Soto, M.; Mansour, M.K.; Sater, M.R.A.; Huntley, M.H.; Turbett, S.; Chung, R.T.; Chen, Y.B.; Hohmann, E.L. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N. Engl. J. Med., 2019, 381(21), 2043-2050.
[http://dx.doi.org/10.1056/NEJMoa1910437] [PMID: 31665575]
[41]
Qiu, R. Cross cultural perspectives on ethics and regulation of fecal microbiota for transplantation. AME Med. J., 2017, 2(7)
[http://dx.doi.org/10.21037/amj.2017.06.12]
[42]
Smith, M.; Kassam, Z.; Edelstein, C.; Burgess, J.; Alm, E. OpenBiome remains open to serve the medical community. Nat. Biotechnol., 2014, 32(9), 867-867.
[http://dx.doi.org/10.1038/nbt.3006] [PMID: 25203030]
[43]
Vargason, A.M.; Anselmo, A.C. Clinical translation of microbe-based therapies: Current clinical landscape and preclinical outlook. Bioeng. Transl. Med., 2018, 3(2), 124-137.
[http://dx.doi.org/10.1002/btm2.10093] [PMID: 30065967]
[44]
Sadowsky, M.J.; Khoruts, A.; Weingarden, A.R.; Hamilton, M.J. Compositions and methods for transplantation of colon microbiota. World Patent WO2012122478A1 2012.
[45]
Sadowsky, M.J.; Khoruts, A.; Hamilton, M.J.; Bobr, A.; Weingarden, A.R. Freeze dried fecal microbiota for use in fecal microbial transplantation. World Patent WO2014152484A1 2014.
[46]
Jones, L.A.; Jones, C.R.; Hlavka, E.J.; Gordon, R.D. Microbiota restoration therapy (MRT), compositions and methods of manufacture. U.S. Patent US20150050246A1 2015.
[47]
Borody, T.J. Compositions for the restoration of a fecal microbiota and methods for making and using them. World Patent WO2014078911A1 2014.
[48]
Schneider, J.; Kim, Y.G.; Olle, B.; Reddy, S.; Norman, J.; Patarroyo, J. Treatment of Clostridium difficile infection. U.S. Patent US10064904B2 2018.
[49]
McKenzie, G.; McKenzie, M.J.L.; Cook, D.N.; Vulic, M.; Von Maltzahn, G.; Goodman, B.; Aunins, J.G.; Henn, M.R.; Berry, D.A.; Winkler, J. Compositions and methods. World Patent WO2014121302A2, Aug. 7, 2014. 2014.
[50]
Dupont, H.L.; Jiang, Z.D. Compositions and methods for fecal microbiota transplantation. World Patent WO2018140931A1 2018.
[51]
Borody, T.J. Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them. U. S. Patent US9901603B2 2018.
[52]
Hamilton, M.J.; Khoruts, A.; Sadowsky, M.J.; Staley, C.M. Compositions and methods for C. difficile treatment. U. S. Patent US20190247445A1 2019.
[53]
Siew Chien, N.G.; Zuo, T. Fecal virome and therapeutic efficacy of fecal microbiota transplantation. U. S. Patent US20190321421A1 2019.
[54]
Quraishi, M.N.; Widlak, M.; Bhala, N.; Moore, D.; Price, M.; Sharma, N.; Iqbal, T.H. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment. Pharmacol. Ther., 2017, 46(5), 479-493.
[http://dx.doi.org/10.1111/apt.14201] [PMID: 28707337]
[55]
A review of 10 years of human microbiome research activities at the US National Institutes of Health, Fiscal Years 2007-2016. Microbiome, 2019, 7(1), 31.
[http://dx.doi.org/10.1186/s40168-019-0620-y] [PMID: 30808411]
[56]
Ossorio, P.N.; Zhou, Y. FMT and microbial medical products: generating high-quality evidence through good governance. J. Law Med. Ethics, 2019, 47(4), 505-523.
[http://dx.doi.org/10.1177/1073110519897727] [PMID: 31957588]
[57]
Ratner, M. Microbial cocktails join fecal transplants in IBD treatment trials. Nat. Biotechnol., 2015, 33(8), 787-788.
[http://dx.doi.org/10.1038/nbt0815-787] [PMID: 26252119]
[58]
https://www.vedantabio.com/news-media/press-releases/detail/2298/vedanta-biosciences-announces-initiation-of-phase-1a1b2020.
[59]
McGovern, B.H.; Ford, C.B.; Henn, M.R.; Pardi, D.S.; Khanna, S.; Hohmann, E.L.; O’Brien, E.J.; Desjardins, C.A.; Bernardo, P.; Wortman, J.R.; Lombardo, M.J.; Litcofsky, K.D.; Winkler, J.A.; McChalicher, C.W.J.; Li, S.S.; Tomlinson, A.D.; Nandakumar, M.; Cook, D.N.; Pomerantz, R.J.; Auninš, J.G.; Trucksis, M. SER-109, an investigational microbiome drug to reduce recurrence after Clostridioides difficile infection: lessons learned from a phase 2 trial. Clin. Infect. Dis., 2020.ciaa387
[http://dx.doi.org/10.1093/cid/ciaa387] [PMID: 32255488]

Rights & Permissions Print Cite
Article Metrics
14
2
© 2024 Bentham Science Publishers | Privacy Policy